ORIC PHARMACEUTICALS, INC. Basic Shares Outstanding (Weighted Average)
ORIC PHARMACEUTICALS, INC. (ORIC) reported Basic Shares Outstanding (Weighted Average) of 108.01 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 108.01M shares, a 38.25% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 105.47M shares, a 48.47% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 102.75M shares, a 45.41% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 98.95M shares, a 40.27% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 87.79M shares, a 25.91% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 69.73M shares, a 35.52% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 51.45M shares, a 29.75% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 39.66M shares, a 4.48% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 108.01M shares 10-Q · filed 2026-08-03 | 106.75M shares 10-Q · filed 2026-08-03 | 105.41M shares derived: average of 3 quarters · filed 2026-08-03 | 103.80M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 105.47M shares 10-Q · filed 2026-05-04 | 104.11M shares derived: average of 2 quarters · filed 2026-05-04 | 102.39M shares derived: average of 3 quarters · filed 2026-05-04 | 96.33M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | 102.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 100.85M shares derived: average of 2 quarters · filed 2026-02-23 | 93.28M shares derived: average of 3 quarters · filed 2026-08-03 | 87.79M shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 98.95M shares 10-Q · filed 2025-11-13 | 88.54M shares derived: average of 2 quarters · filed 2026-08-03 | 82.81M shares 10-Q · filed 2025-11-13 | 79.69M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | 78.13M shares 10-Q · filed 2026-08-03 | 74.60M shares 10-Q · filed 2026-08-03 | 73.28M shares derived: average of 3 quarters · filed 2026-08-03 | 72.59M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | 71.04M shares 10-Q · filed 2026-05-04 | 70.85M shares derived: average of 2 quarters · filed 2026-05-04 | 70.75M shares derived: average of 3 quarters · filed 2026-05-04 | 70.65M shares derived: average of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | 70.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 70.60M shares derived: average of 2 quarters · filed 2026-02-23 | 70.52M shares derived: average of 3 quarters · filed 2026-02-23 | 69.73M shares 10-K · filed 2026-02-23 |
| 2024-09-30 | 70.54M shares 10-Q · filed 2025-11-13 | 70.45M shares derived: average of 2 quarters · filed 2025-11-13 | 69.42M shares 10-Q · filed 2025-11-13 | 66.44M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 70.35M shares 10-Q · filed 2025-08-12 | 68.85M shares 10-Q · filed 2025-08-12 | 65.08M shares derived: average of 3 quarters · filed 2025-08-12 | 63.16M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 67.35M shares 10-Q · filed 2025-05-05 | 62.44M shares derived: average of 2 quarters · filed 2025-05-05 | 60.76M shares derived: average of 3 quarters · filed 2025-05-05 | 56.98M shares derived: average of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | 57.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | 57.47M shares derived: average of 2 quarters · filed 2025-02-18 | 53.53M shares derived: average of 3 quarters · filed 2025-02-18 | 51.45M shares 10-K · filed 2025-02-18 |
| 2023-09-30 | 57.40M shares 10-Q · filed 2024-11-12 | 51.53M shares derived: average of 2 quarters · filed 2024-11-12 | 49.42M shares 10-Q · filed 2024-11-12 | 47.07M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 45.65M shares 10-Q · filed 2024-08-12 | 45.37M shares 10-Q · filed 2024-08-12 | 43.62M shares derived: average of 3 quarters · filed 2024-08-12 | 42.61M shares derived: average of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | 45.09M shares 10-Q · filed 2024-05-06 | 42.61M shares derived: average of 2 quarters · filed 2024-05-06 | 41.60M shares derived: average of 3 quarters · filed 2024-05-06 | 41.07M shares derived: average of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | 40.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 39.85M shares derived: average of 2 quarters · filed 2024-03-11 | 39.73M shares derived: average of 3 quarters · filed 2024-03-11 | 39.66M shares 10-K · filed 2024-03-11 |
| 2022-09-30 | 39.58M shares 10-Q · filed 2023-11-06 | 39.53M shares derived: average of 2 quarters · filed 2023-11-06 | 39.50M shares 10-Q · filed 2023-11-06 | 39.47M shares derived: average of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | 39.48M shares 10-Q · filed 2023-08-10 | 39.46M shares 10-Q · filed 2023-08-10 | 39.44M shares derived: average of 3 quarters · filed 2023-08-10 | 39.33M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 39.43M shares 10-Q · filed 2023-05-08 | 39.42M shares derived: average of 2 quarters · filed 2023-05-08 | 39.28M shares derived: average of 3 quarters · filed 2023-05-08 | 38.64M shares derived: average of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | 39.40M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 39.21M shares derived: average of 2 quarters · filed 2023-03-16 | 38.37M shares derived: average of 3 quarters · filed 2023-03-16 | 37.95M shares 10-K · filed 2023-03-16 |
| 2021-09-30 | 39.01M shares 10-Q · filed 2022-11-07 | 37.85M shares derived: average of 2 quarters · filed 2022-11-07 | 37.47M shares 10-Q · filed 2022-11-07 | |
| 2021-06-30 | 36.70M shares 10-Q · filed 2022-08-11 | 36.69M shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |